Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
Gilles Montalescot, MD, PhD*,
Jean Philippe Collet, MD, PhD*,
Linda Lison, MD*,
R.émi Choussat, MD*,
Annick Ankri, MD ,
Eric Vicaut, MD, PhD ,
Katy Perlemuter, MD*,
François Philippe, MD*,
G.érard Drobinski, MD, PhD* and
Daniel Thomas, MD*
* Department of Cardiology, Pitié-Salpétrière Hospital, Paris, France
Laboratory of Hemostasis, Pitié-Salpétrière Hospital, Paris, France
Laboratory of Biophysics, F. Widal Hospital, Paris, France
View larger version (35K):
[in a new window]
|
Figure 1 Absolute changes of von Willebrand factor levels over 48 h in patients receiving either enoxaparin, unfractionated heparin, PEG-hirudin, or dalteparin. Differences among treatment groups were analyzed by ANOVA and post hoc t tests with Bonferroni correction for multiple comparisons: after correction, comparisons were significant if p value was less than 0.0083.  von Willebrand factor was significantly lowered with PEG-hirudin and enoxaparin compared to unfractionated heparin.
|
|
View larger version (31K):
[in a new window]
|
Figure 2 The rise of von Willebrand factor over the first 48 h identified high-risk patients with a significant difference after univariate comparisons (p < 0.05) between patients with an end point and those free of end points at one-month follow-up. A similar trend was present for each parameter of the composite end point. Checkered bars = patients free of event at 30 days; Open bars = patients with an event at 30 days.
|
|
|
